BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liang J, Ding T, Guo ZW, Yu XJ, Hu YZ, Zheng L, Xu J. Expression pattern of tumour-associated antigens in hepatocellular carcinoma: association with immune infiltration and disease progression. Br J Cancer. 2013;109:1031-1039. [PMID: 23868000 DOI: 10.1038/bjc.2013.390] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Jebar AH, Vile RG, Melcher AA, Griffin S, Selby PJ, Errington-mais F. Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma. Journal of General Virology 2015;96:1533-50. [DOI: 10.1099/vir.0.000098] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
2 Kelley RK, Magbanua MJ, Butler TM, Collisson EA, Hwang J, Sidiropoulos N, Evason K, McWhirter RM, Hameed B, Wayne EM. Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls. BMC Cancer. 2015;15:206. [PMID: 25884197 DOI: 10.1186/s12885-015-1195-z] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 9.4] [Reference Citation Analysis]
3 Woller N, Engelskircher SA, Wirth T, Wedemeyer H. Prospects and Challenges for T Cell-Based Therapies of HCC. Cells 2021;10:1651. [PMID: 34209393 DOI: 10.3390/cells10071651] [Reference Citation Analysis]
4 Zang C, Zhao Y, Qin L, Liu G, Sun J, Li K, Zhao Y, Sheng S, Zhang H, He N, Zhao P, Wang Q, Li X, Peng Y, Dong T, Zhang Y. Distinct tumour antigen-specific T-cell immune response profiles at different hepatocellular carcinoma stages. BMC Cancer 2021;21:1007. [PMID: 34496797 DOI: 10.1186/s12885-021-08720-9] [Reference Citation Analysis]
5 Moudi B, Heidari Z, Mahmoudzadeh-Sagheb H. Meta-analysis and systematic review of prognostic significance of Glypican-3 in patients with hepatitis B-related hepatocellular carcinoma. Virusdisease 2019;30:193-200. [PMID: 31179356 DOI: 10.1007/s13337-019-00517-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
6 Amado V, González-Rubio S, Zamora J, Alejandre R, Espejo-Cruz ML, Linares C, Sánchez-Frías M, García-Jurado G, Montero JL, Ciria R, Rodríguez-Perálvarez M, Ferrín G, De la Mata M. Clearance of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Undergoing Surgical Resection or Liver Transplantation. Cancers (Basel) 2021;13:2476. [PMID: 34069569 DOI: 10.3390/cancers13102476] [Reference Citation Analysis]
7 Wang H, Chen D, Wang R, Quan W, Xia D, Mei J, Xu J, Liu C. NY-ESO-1 expression in solid tumors predicts prognosis: A systematic review and meta-analysis. Medicine (Baltimore) 2019;98:e17990. [PMID: 31770209 DOI: 10.1097/MD.0000000000017990] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
8 Tsang O, Wong JWH. Proteogenomic interrogation of cancer cell lines: an overview of the field. Expert Rev Proteomics 2021;18:221-32. [PMID: 33877947 DOI: 10.1080/14789450.2021.1914594] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Wirth TC, Kühnel F. Neoantigen Targeting-Dawn of a New Era in Cancer Immunotherapy? Front Immunol 2017;8:1848. [PMID: 29312332 DOI: 10.3389/fimmu.2017.01848] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 10.2] [Reference Citation Analysis]
10 Zhou L, Zhu Y. The EpCAM overexpression is associated with clinicopathological significance and prognosis in hepatocellular carcinoma patients: A systematic review and meta-analysis. International Journal of Surgery 2018;56:274-80. [DOI: 10.1016/j.ijsu.2018.06.025] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
11 Sideras K, Bots SJ, Biermann K, Sprengers D, Polak WG, IJzermans JN, de Man RA, Pan Q, Sleijfer S, Bruno MJ, Kwekkeboom J. Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area.Br J Cancer. 2015;112:1911-1920. [PMID: 26057582 DOI: 10.1038/bjc.2015.92] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
12 Sanceau J, Gougelet A. Epigenetic mechanisms of liver tumor resistance to immunotherapy. World J Hepatol 2021; 13(9): 979-1002 [PMID: 34630870 DOI: 10.4254/wjh.v13.i9.979] [Reference Citation Analysis]
13 Seifi-Alan M, Shamsi R, Ghafouri-Fard S. Application of cancer-testis antigens in immunotherapy of hepatocellular carcinoma. Immunotherapy 2018;10:411-21. [PMID: 29473472 DOI: 10.2217/imt-2017-0154] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
14 Siliņa K, Rulle U, Kalniņa Z, Linē A. Manipulation of tumour-infiltrating B cells and tertiary lymphoid structures: a novel anti-cancer treatment avenue? Cancer Immunol Immunother 2014;63:643-62. [DOI: 10.1007/s00262-014-1544-9] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
15 Xue R, Feng J, Meng Q, Lv F, Zhu Y, Yu H, Zhang S, Song C, Sun L, Yue Z, Feng S, Che R, Xiang Q, Jing X. The significance of glypican-3 expression profiling in the tumor cellular origin theoretical system for hepatocellular carcinoma progression. J Gastroenterol Hepatol 2017;32:1503-11. [PMID: 28087980 DOI: 10.1111/jgh.13736] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
16 Grizzi F, Qehajaj D, Chiriva-Internati M, Stifter S. Comment on 'Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area'. Br J Cancer 2016;114:e1. [PMID: 27077695 DOI: 10.1038/bjc.2015.441] [Reference Citation Analysis]
17 Atay S. Evaluation of tumoral glypican 3 mRNA level as a diagnostic and prognostic biomarker for hepatitis-b virus-associated hepatocellular carcinoma by an integrative transcriptomic meta-analysis and bioinformatics. ETD. [DOI: 10.19161/etd.1127225] [Reference Citation Analysis]
18 Xiao WK, Qi CY, Chen D, Li SQ, Fu SJ, Peng BG, Liang LJ. Prognostic significance of glypican-3 in hepatocellular carcinoma: a meta-analysis. BMC Cancer. 2014;14:104. [PMID: 24548704 DOI: 10.1186/1471-2407-14-104] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
19 Greve KB, Pøhl M, Olsen KE, Nielsen O, Ditzel HJ, Gjerstorff MF. SSX2-4 expression in early-stage non-small cell lung cancer. Tissue Antigens 2014;83:344-9. [PMID: 24645645 DOI: 10.1111/tan.12340] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
20 Bertino G, Demma S, Ardiri A, Proiti M, Mangia A, Gruttadauria S, Toro A, Di Carlo I, Malaguarnera G, Bertino N. The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies. Biomed Res Int. 2015;2015:731469. [PMID: 25893197 DOI: 10.1155/2015/731469] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
21 Zhou F, Shang W, Yu X, Tian J. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment. Med Res Rev. 2018;38:741-767. [PMID: 28621802 DOI: 10.1002/med.21455] [Cited by in Crossref: 87] [Cited by in F6Publishing: 100] [Article Influence: 17.4] [Reference Citation Analysis]
22 Tallima H, Azzazy HME, El Ridi R. Cell surface sphingomyelin: key role in cancer initiation, progression, and immune evasion. Lipids Health Dis 2021;20:150. [PMID: 34717628 DOI: 10.1186/s12944-021-01581-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Buonaguro L, Mauriello A, Cavalluzzo B, Petrizzo A, Tagliamonte M. Immunotherapy in hepatocellular carcinoma. Ann Hepatol. 2019;18:291-297. [PMID: 31047849 DOI: 10.1016/j.aohep.2019.04.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 33] [Article Influence: 8.0] [Reference Citation Analysis]
24 Ostroumov D, Fekete-Drimusz N, Saborowski M, Kühnel F, Woller N. CD4 and CD8 T lymphocyte interplay in controlling tumor growth. Cell Mol Life Sci 2018;75:689-713. [PMID: 29032503 DOI: 10.1007/s00018-017-2686-7] [Cited by in Crossref: 135] [Cited by in F6Publishing: 132] [Article Influence: 27.0] [Reference Citation Analysis]
25 Jeon Y, Kim H, Jang ES, Hong S, Kim JW, Yoon YS, Cho JY, Han HS, Jeong SH. Expression profile and prognostic value of glypican-3 in post-operative South Korean hepatocellular carcinoma patients. APMIS 2016;124:208-15. [PMID: 26764243 DOI: 10.1111/apm.12491] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
26 Jayant K, Habib N, Huang KW, Warwick J, Arasaradnam R. Recent Advances: The Imbalance of Immune Cells and Cytokines in the Pathogenesis of Hepatocellular Carcinoma. Diagnostics (Basel). 2020;10. [PMID: 32466214 DOI: 10.3390/diagnostics10050338] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
27 Zhang J, Zhang M, Ma H, Song X, He L, Ye X, Li X. Overexpression of glypican-3 is a predictor of poor prognosis in hepatocellular carcinoma: An updated meta-analysis. Medicine (Baltimore) 2018;97:e11130. [PMID: 29901640 DOI: 10.1097/MD.0000000000011130] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
28 Liu CY, Chen KF, Chen PJ. Treatment of Liver Cancer. Cold Spring Harb Perspect Med 2015;5:a021535. [PMID: 26187874 DOI: 10.1101/cshperspect.a021535] [Cited by in Crossref: 85] [Cited by in F6Publishing: 91] [Article Influence: 12.1] [Reference Citation Analysis]
29 Montella L, Sarno F, Ambrosino A, Facchini S, D'Antò M, Laterza MM, Fasano M, Quarata E, Ranucci RAN, Altucci L, Berretta M, Facchini G. The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma. Cells 2021;10:1909. [PMID: 34440678 DOI: 10.3390/cells10081909] [Reference Citation Analysis]
30 Kong C, Zhang C, Wu Y, Zeng Z, Yu H, Zeng J, Lei S, He J, Fan P. The expression and meaning of CD68, CD163, CD57, and IgG4 in granulomatous lobular mastitis. Gland Surg 2020;9:936-49. [PMID: 32953603 DOI: 10.21037/gs-20-419] [Reference Citation Analysis]
31 Aerts M, Benteyn D, Van Vlierberghe H, Thielemans K, Reynaert H. Current status and perspectives of immune-based therapies for hepatocellular carcinoma. World J Gastroenterol 2016; 22(1): 253-261 [PMID: 26755874 DOI: 10.3748/wjg.v22.i1.253] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
32 Armstrong SA, He AR. Immuno-oncology for Hepatocellular Carcinoma: The Present and the Future. Clin Liver Dis 2020;24:739-53. [PMID: 33012456 DOI: 10.1016/j.cld.2020.07.007] [Reference Citation Analysis]